Last reviewed: November 2017
Last updated: October  2017

Summary

Details

  • Key highlights
  • Algorithms and tables
  • Indications for anticoagulation
  • Contraindications: absolute and relative contraindications
  • Contraindications: bleeding risk assessment
  • Contraindications: outcome event assessment
  • Initiating anticoagulation in primary care
  • Initiating anticoagulation in secondary care: initial therapy
  • Initiating anticoagulation in secondary care: transitioning to oral therapy
  • Initiating anticoagulation in patients with HIT
  • Warfarin initiation protocols
  • Maintenance therapy: venous thromboembolism
  • Maintenance therapy: atrial fibrillation
  • Maintenance therapy: clinical re-evaluation
  • Monitoring: general principles
  • Monitoring: warfarin
  • Monitoring: parenteral anticoagulants
  • Monitoring: direct oral anticoagulants
  • Surgery/procedure in anticoagulated patient: general principles
  • Surgery/procedure in anticoagulated patient: management algorithm
  • Special populations: pregnancy
  • Special populations: breast-feeding
  • Special populations: children
  • Special populations: older patients
  • Special populations: renal impairment
  • Special populations: hepatic impairment
  • Special populations: patients on antiplatelet therapy
  • Complications: adverse effects
  • Complications: bleeding
  • Complications: management of bleeding
  • Reversal agents: general principles
  • Reversal agents: for heparins
  • Reversal agents: for warfarin
  • Reversal agents: for direct oral anticoagulants (DOACs)
  • Anticoagulants: vitamin K antagonists
  • Anticoagulants: oral factor II inhibitors
  • Anticoagulants: oral factor Xa inhibitors
  • Anticoagulants: unfractionated heparin (UFH)
  • Anticoagulants: low molecular weight heparins (LMWHs)
  • Anticoagulants: parenteral factor Xa inhibitors
  • Anticoagulants: heparinoids
  • Anticoagulants: hirudins
  • Anticoagulants: argatroban
  • Patient information

Contributors

Authors VIEW ALL

Director

Thrombosis Clinic

Intermountain Medical Center

Murray

Professor of Medicine

University of Utah

Salt Lake City

UT

Disclosures

SMS has served as a panelist for the American College of Chest Physicians' 10th edition of the guideline for antithrombotic therapy for VTE disease; has served as a panelist for the Anticoagulation Forum initiative on clinical guidance management of venous thromboembolism; and has been awarded grant funding paid to his employer (Intermountain Healthcare) from Bristol-Meyers Squibb.

Director

Thrombosis Clinic

Intermountain Medical Center

Murray

Professor of Medicine

University of Utah

Salt Lake City

UT

Disclosures

SCW has served as a panelist for the American College of Chest Physicians' 10th edition of the guideline for antithrombotic therapy for VTE disease; has served as a panelist for the Anticoagulation Forum initiative on clinical guidance management of venous thromboembolism; and has been awarded grant funding paid to his employer (Intermountain Healthcare) from Bristol-Meyers Squibb and Iverson Genetics.

Ambulatory Care Clinical Pharmacy Specialist

VA Palo Alto Health Care System

Palo Alto

CA

Disclosures

ESC declares that she has no competing interests.

Peer reviewers VIEW ALL

Associate Professor

Department of Medicine

McMaster University

Thrombosis Consultant

Juravinski Hospital and Cancer Centre

Hamilton

Ontario

Canada

Disclosures

LL has been reimbursed for educational lectures for Pfizer Canada (Fragmin; dalteparin) and has received lecture honoraria and research funding from Bayer, Inc (Xarelto; rivaroxaban).

Senior Staff Hospitalist

Medical Director for Professional Development and Research

Division of Hospital Medicine

Henry Ford Hospital

Detroit

MI

Disclosures

SK has received speaker honorarium from Janssen, Boehringer-Ingelheim, Bristol Myer Squibb/Pfizer, CSL Behring, and Daiichi Sankyo; he has served as a consultant for Boehringer-Ingelheim, Bristol Myer Squibb/Pfizer, Janssen, Daiichi Sankyo, and Portola; he also is a board member (non-profit) of the Thrombosis and Hemostasis Societies of North America, the AC Forum, the National Certification Board of Anticoagulation Providers, and the National Blood Clot Alliance Medical and Scientific Advisory Board.

Use of this content is subject to our disclaimer